Emmanuel Volanakis, MD

Emmanuel Volanakis, MD

Assistant Professor of Pediatrics
Hematology/Oncology
Preston Research Building
2220 Pierce Avenue
Room / Suite
397
Nashville
Tennessee
37232-6311
(615) 936-1762

Specialty
Hematology/Oncology, Pediatric
M.D.
University of Alabama School of Medicine, Birmingham, AL, 2001
Residency
Pediatrics Residency-Baylor College of Medicine, Houston, TX
Fellowships
Cell and Gene Therapy Postdoctoral Fellow-Baylor College of Medicine, Houston, TX
Pediatrics Hematology/Oncology Fellowship-St. Jude Children's Research Hospital, Memphis, TX

Clinical Interests

Sickle cell disease, thalassemia  

Research Information

Dr. Emmanuel Volanakis is interested in the clinical care of children and young adults with sickle cell disease and other hemoglobinopathies. He has served as the site investigator for industry sponsored and investigator initiated multicenter clinical trials.  Dr. Emmanuel Volanakis is a graduate of the University of Alabama School of Medicine. He completed his Pediatrics training at Baylor College of Medicine and his Pediatric Hematology/Oncology training at St Jude Children's Research Hospital. He is interested in the care of children and young adults with sickle cell disease. He has served as the site investigator for industry sponsored and investigator initiated multicenter clinical trials. Most recently, he was the site investigator for the HOPE trial of voxelotor, an anti-sickling agent that has been shown to increase hemoglobin levels and reduce markers of hemolysis in individuals with sickle cell disease. He was the Vanderbilt lead for the DISPLACE study, a three-part implementation science study of stroke screening. The first part measured the adherence to national guidelines for screening children with sickle cell disease for stroke risk using transcranial Doppler ultrasound. The second part explored the barriers to screening, and the third part will test provider-facing and patient-facing strategies for improving adherence. Through these efforts, we have been able to provide our patients with access to cutting edge therapeutic agents and evidence-based clinical practice.